Ilan Y, Attavar P, Takahashi M, Davidson A, Horwitz M S, Guida J, Chowdhury N R, Chowdhury J R
Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
J Clin Invest. 1996 Dec 1;98(11):2640-7. doi: 10.1172/JCI119085.
Recombinant adenoviruses are highly efficient at transferring foreign genes in vivo. However, duration of gene expression is limited by the host antiviral immune response which precludes expression upon viral readministration. We tested the feasibility of prolonging gene expression by induction of central tolerance to adenoviral antigens in bilirubin-UDP-glucuronosyltransferase-1 (BUGT1)-deficient Gunn rats. Tolerance was induced by intraperitoneal injection of antilymphocyte serum, followed by intrathymic inoculation of one of the following: a recombinant adenovirus (Ad), adenovirus human UDP-glucuronosyltransferase (Ad-hBUGT1) carrying the hBUGT1 gene; a protein extract of the same virus; or viral infected hepatocytes. Controls received intrathymic injections of normal saline. After 12 d all groups were injected intravenously with 5 x 10(9) pfu of either Ad-hBUGT1 or adenovirus beta-galactosidase (Ad-LacZ) (expressing the Escherichia coli beta-galactosidase [LacZ] gene). In all three groups of tolerized rats, hBUGT1 was expressed in the liver after administration of Ad-hBUGT1, with glucuronidation of biliary bilirubin of above 95%. Serum bilirubin levels decreased from 7.2 to 1.8 mg/dl within 1 wk and remained low for 7 wk. Similar findings were observed following repeat injections given on days 45 and 112. In control rats serum bilirubin levels were reduced for only 4 wk, and viral readministration was ineffective. In all tolerized groups, but not in controls, there was a marked inhibition of appearance of neutralizing antibodies and cytotoxic lymphocytes against the recombinant adenovirus. Injection of wild type adenovirus-5 (Ad5) into the tolerized rats elicited a wild type-specific cytotoxic lymphocyte response. This is the first demonstration of Ad-directed long-term correction of an inherited metabolic disease following central tolerization with thymic antigen.
重组腺病毒在体内转移外源基因方面效率很高。然而,基因表达的持续时间受到宿主抗病毒免疫反应的限制,这使得病毒再次给药后无法表达。我们在胆红素 - UDP - 葡萄糖醛酸基转移酶 - 1(BUGT1)缺陷的冈恩大鼠中测试了通过诱导对腺病毒抗原的中枢耐受来延长基因表达的可行性。通过腹腔注射抗淋巴细胞血清诱导耐受,随后进行胸腺内接种以下之一:重组腺病毒(Ad)、携带hBUGT1基因的腺病毒人UDP - 葡萄糖醛酸基转移酶(Ad - hBUGT1);同一病毒的蛋白提取物;或病毒感染的肝细胞。对照组接受胸腺内注射生理盐水。12天后,所有组均静脉注射5×10⁹ pfu的Ad - hBUGT1或腺病毒β - 半乳糖苷酶(Ad - LacZ)(表达大肠杆菌β - 半乳糖苷酶[LacZ]基因)。在所有三组耐受大鼠中,给予Ad - hBUGT1后肝脏中表达了hBUGT1,胆汁胆红素的葡萄糖醛酸化率高于95%。血清胆红素水平在1周内从7.2降至1.8 mg/dl,并在7周内保持较低水平。在第45天和第112天重复注射后观察到类似结果。在对照大鼠中,血清胆红素水平仅降低了4周,再次给予病毒无效。在所有耐受组中,但对照组中没有,针对重组腺病毒的中和抗体和细胞毒性淋巴细胞的出现受到明显抑制。向耐受大鼠注射野生型腺病毒5(Ad5)引发了野生型特异性细胞毒性淋巴细胞反应。这是首次证明经胸腺抗原中枢耐受后,腺病毒对遗传性代谢疾病进行长期纠正。